WO2003049700B1 - Supplementation induite par les plasmides dans le traitement de maladies chroniques affectant des sujets - Google Patents
Supplementation induite par les plasmides dans le traitement de maladies chroniques affectant des sujetsInfo
- Publication number
- WO2003049700B1 WO2003049700B1 PCT/US2002/039509 US0239509W WO03049700B1 WO 2003049700 B1 WO2003049700 B1 WO 2003049700B1 US 0239509 W US0239509 W US 0239509W WO 03049700 B1 WO03049700 B1 WO 03049700B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ghrh
- seqid
- canceled
- subject
- biological equivalent
- Prior art date
Links
- 101710142969 Somatoliberin Proteins 0.000 title claims abstract 175
- 208000017667 Chronic Disease Diseases 0.000 title claims 10
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 title claims 10
- 102000038461 Growth Hormone-Releasing Hormone Human genes 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract 278
- 102100022831 Somatoliberin Human genes 0.000 claims abstract 174
- 150000007523 nucleic acids Chemical class 0.000 claims abstract 89
- 108020004707 nucleic acids Proteins 0.000 claims abstract 88
- 102000039446 nucleic acids Human genes 0.000 claims abstract 88
- 241001465754 Metazoa Species 0.000 claims abstract 25
- 206010028980 Neoplasm Diseases 0.000 claims abstract 14
- 230000000694 effects Effects 0.000 claims abstract 14
- 230000012010 growth Effects 0.000 claims abstract 7
- 108090000623 proteins and genes Proteins 0.000 claims abstract 7
- 201000011510 cancer Diseases 0.000 claims abstract 4
- 208000007502 anemia Diseases 0.000 claims abstract 3
- 238000001727 in vivo Methods 0.000 claims abstract 2
- 230000001105 regulatory effect Effects 0.000 claims abstract 2
- 150000001413 amino acids Chemical group 0.000 claims 102
- 229940024606 amino acid Drugs 0.000 claims 90
- 235000001014 amino acid Nutrition 0.000 claims 90
- 229920001184 polypeptide Polymers 0.000 claims 88
- 102000004196 processed proteins & peptides Human genes 0.000 claims 88
- 108090000765 processed proteins & peptides Proteins 0.000 claims 88
- 210000001519 tissue Anatomy 0.000 claims 68
- 210000004027 cell Anatomy 0.000 claims 53
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 38
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 38
- 235000004279 alanine Nutrition 0.000 claims 38
- 235000013350 formula milk Nutrition 0.000 claims 38
- 108010051696 Growth Hormone Proteins 0.000 claims 23
- 102000018997 Growth Hormone Human genes 0.000 claims 23
- 239000000122 growth hormone Substances 0.000 claims 20
- 230000028327 secretion Effects 0.000 claims 20
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 19
- 239000004471 Glycine Substances 0.000 claims 19
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 19
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 19
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 19
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 19
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 19
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 19
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 19
- 229960001230 asparagine Drugs 0.000 claims 19
- 235000009582 asparagine Nutrition 0.000 claims 19
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 19
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 19
- 239000004474 valine Substances 0.000 claims 19
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 18
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 18
- 229960000310 isoleucine Drugs 0.000 claims 18
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 18
- 229930182817 methionine Natural products 0.000 claims 18
- 210000003205 muscle Anatomy 0.000 claims 12
- 229920002643 polyglutamic acid Polymers 0.000 claims 12
- 108020005345 3' Untranslated Regions Proteins 0.000 claims 10
- 201000009030 Carcinoma Diseases 0.000 claims 10
- 108091036066 Three prime untranslated region Proteins 0.000 claims 7
- 239000002253 acid Substances 0.000 claims 7
- 210000000663 muscle cell Anatomy 0.000 claims 7
- 210000001082 somatic cell Anatomy 0.000 claims 7
- 210000001988 somatic stem cell Anatomy 0.000 claims 7
- 108010000521 Human Growth Hormone Proteins 0.000 claims 6
- 102000002265 Human Growth Hormone Human genes 0.000 claims 6
- 239000000854 Human Growth Hormone Substances 0.000 claims 6
- 235000013305 food Nutrition 0.000 claims 6
- 239000005556 hormone Substances 0.000 claims 6
- 229940088597 hormone Drugs 0.000 claims 6
- 230000003612 virological effect Effects 0.000 claims 6
- 101710184997 Actin, gamma-enteric smooth muscle Proteins 0.000 claims 5
- 102100022454 Actin, gamma-enteric smooth muscle Human genes 0.000 claims 5
- 235000020616 amino acid formula Nutrition 0.000 claims 5
- 230000004071 biological effect Effects 0.000 claims 5
- 108010006025 bovine growth hormone Proteins 0.000 claims 5
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims 5
- 239000010931 gold Substances 0.000 claims 5
- 229910052737 gold Inorganic materials 0.000 claims 5
- 238000002347 injection Methods 0.000 claims 5
- 239000007924 injection Substances 0.000 claims 5
- 239000002245 particle Substances 0.000 claims 5
- 230000002792 vascular Effects 0.000 claims 5
- 206010025323 Lymphomas Diseases 0.000 claims 4
- 208000032839 leukemia Diseases 0.000 claims 4
- 239000003488 releasing hormone Substances 0.000 claims 4
- 208000003200 Adenoma Diseases 0.000 claims 3
- 206010001233 Adenoma benign Diseases 0.000 claims 3
- 208000001647 Renal Insufficiency Diseases 0.000 claims 3
- 206010039491 Sarcoma Diseases 0.000 claims 3
- 201000006370 kidney failure Diseases 0.000 claims 3
- 201000006512 mast cell neoplasm Diseases 0.000 claims 3
- 201000001441 melanoma Diseases 0.000 claims 3
- 210000003743 erythrocyte Anatomy 0.000 claims 2
- 208000026278 immune system disease Diseases 0.000 claims 2
- 230000006510 metastatic growth Effects 0.000 claims 2
- 230000008488 polyadenylation Effects 0.000 claims 2
- 230000001629 suppression Effects 0.000 claims 2
- 210000004881 tumor cell Anatomy 0.000 claims 2
- NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical compound NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 230000004584 weight gain Effects 0.000 claims 1
- 235000019786 weight gain Nutrition 0.000 claims 1
- 230000004580 weight loss Effects 0.000 claims 1
- 230000000979 retarding effect Effects 0.000 abstract 4
- 206010006895 Cachexia Diseases 0.000 abstract 2
- 230000001939 inductive effect Effects 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 238000004520 electroporation Methods 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000001151 other effect Effects 0.000 abstract 1
- 239000013612 plasmid Substances 0.000 abstract 1
- 230000009469 supplementation Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Virology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention porte sur des compositions et sur des procédés utilisés dans la supplémentation induite par des plasmides. Les compositions et les procédés de cette invention sont utiles pour retarder la croissance de la tumeur et la cachexie, la maladie des avortons, l'anémie et autres effets qui sont communément associés aux animaux atteints d'un cancer. Globalement, les formes d'exécution de cette invention peuvent être réalisées par administration d'une quantité efficace d'un produit de recombinaison de l'expression de l'acide nucléique qui code l'hormone libérant l'hormone de croissance ou son équivalent biologique fonctionnel dans les cellules spécifiques du tissu d'un animal et permettant l'expression du gène codé dans l'animal. Par exemple, lorsqu'une séquence d'acide nucléique est administrée aux cellules spécifiques du tissu de l'animal spécifique de l'expression constitutive. En outre, la régulation externe du gène de l'hormone libérant l'hormone de croissance ou de son équivalent biologique fonctionnel peut être effectuée au moyen de promoteurs inductibles qui sont régulés par des molécules de commutation moléculaire données à l'animal. Le procédé préféré consiste à administrer directement dans les cellules de l'animal par le processus d'électroporation in vivo les séquences constitutives ou inductibles codant l'acide nucléique de l'hormone libérant l'hormone de croissance ou de ses équivalents biologiques fonctionnels. De plus, l'invention porte sur un traitement visant à retarder la croissance de la tumeur et la cachexie ou les effets de la maladie de l'avorton qui sont généralement associés à des tumeurs, ce traitement consistant à administrer à l'animal l'hormone libérant l'hormone de croissance de recombinaison ou son équivalent biologique.
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA2469310A CA2469310C (fr) | 2001-12-11 | 2002-12-10 | Supplementation administree par plasmides pour le traitement de patients a maladie chronique |
| BR0214869-2A BR0214869A (pt) | 2001-12-11 | 2002-12-10 | Suplementação mediada por plasmìdeo para tratamento de indivìduos cronicamente doentes |
| MXPA04005713A MXPA04005713A (es) | 2001-12-11 | 2002-12-10 | Complemento de la hormona de liberacion de la hormona de crecimiento para tratar sujetos cronicamente enfermos. |
| EP02804771.0A EP1465654B1 (fr) | 2001-12-11 | 2002-12-10 | Supplementation induite par les plasmides dans le traitement de maladies chroniques affectant des sujets |
| AU2002357143A AU2002357143B2 (en) | 2001-12-11 | 2002-12-10 | Growth hormone releasing hormone supplementation for treating chronically ill subjects |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33961001P | 2001-12-11 | 2001-12-11 | |
| US60/339,610 | 2001-12-11 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| WO2003049700A2 WO2003049700A2 (fr) | 2003-06-19 |
| WO2003049700A3 WO2003049700A3 (fr) | 2003-09-18 |
| WO2003049700B1 true WO2003049700B1 (fr) | 2003-10-30 |
Family
ID=23329825
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2002/039509 WO2003049700A2 (fr) | 2001-12-11 | 2002-12-10 | Supplementation induite par les plasmides dans le traitement de maladies chroniques affectant des sujets |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US7241744B2 (fr) |
| EP (1) | EP1465654B1 (fr) |
| CN (1) | CN1615151A (fr) |
| AR (1) | AR037778A1 (fr) |
| AU (1) | AU2002357143B2 (fr) |
| BR (1) | BR0214869A (fr) |
| CA (1) | CA2469310C (fr) |
| MX (1) | MXPA04005713A (fr) |
| MY (1) | MY142457A (fr) |
| TW (1) | TW200301778A (fr) |
| WO (1) | WO2003049700A2 (fr) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1578901A4 (fr) * | 2001-09-07 | 2006-03-29 | Baylor College Medicine | Fragments d'adn lineaires destines a l'expression genetique |
| US7338656B2 (en) * | 2001-10-26 | 2008-03-04 | Baylor College Of Medicine | Composition and method to alter lean body mass and bone properties in a subject |
| EP1465654B1 (fr) * | 2001-12-11 | 2015-02-25 | Inovio Pharmaceuticals, Inc. | Supplementation induite par les plasmides dans le traitement de maladies chroniques affectant des sujets |
| AU2003215082B2 (en) * | 2002-02-07 | 2011-11-10 | Baylor College Of Medicine | Modified pituitary gland development in offspring from expectant mother animals treated with growth hormone releasing hormone therapy |
| WO2003099341A1 (fr) * | 2002-05-28 | 2003-12-04 | Advisys, Inc. | Delivrance augmentee d'un produit de recombinaison d'acide nucleique in vivo par le systeme poly-l-glutamate (plg) |
| US20040175727A1 (en) * | 2002-11-04 | 2004-09-09 | Advisys, Inc. | Synthetic muscle promoters with activities exceeding naturally occurring regulatory sequences in cardiac cells |
| TW200424214A (en) * | 2003-04-21 | 2004-11-16 | Advisys Inc | Plasmid mediated GHRH supplementation for renal failures |
| US7468273B2 (en) | 2003-05-01 | 2008-12-23 | Meial Limited | Canine GHRH gene, polypeptides and methods of use |
| CA2575926C (fr) * | 2003-08-04 | 2014-02-25 | Advisys, Inc. | Hormone liberant une hormone de croissance specifique du chien |
| MX2007000893A (es) * | 2004-07-23 | 2007-04-18 | Advisys Inc | La hormona liberadora de hormona de crecimiento mejora la respuesta inmune inducida por la vacunacion. |
| US7846720B2 (en) * | 2005-01-26 | 2010-12-07 | Vgx Pharmaceuticals, Inc. | Optimized high yield synthetic plasmids |
| EP2198881A1 (fr) | 2005-04-25 | 2010-06-23 | Merial Limited | Vaccins contre le virus Nipah |
| US7771995B2 (en) | 2005-11-14 | 2010-08-10 | Merial Limited | Plasmid encoding human BMP-7 |
| EP2186823A1 (fr) | 2005-11-14 | 2010-05-19 | Merial Limited | Thérapie génique pour traiter l'insuffisance rénale |
| WO2011153491A2 (fr) | 2010-06-03 | 2011-12-08 | University Of Miami | Agonistes de l'hormone de libération de l'hormone de croissance en tant qu'effecteurs de la survie et de la prolifération d'îlots pancréatiques |
| US9216213B2 (en) | 2011-04-20 | 2015-12-22 | Merial, Inc. | Adjuvanted rabies vaccine with improved viscosity profile |
| US8993316B2 (en) | 2011-11-16 | 2015-03-31 | Brian P. Hanley | Methods and compositions for gene therapy and GHRH therapy |
| US9079974B2 (en) * | 2011-12-21 | 2015-07-14 | The University Of Miami | GH-RH analogs with potent agonistic effects |
| WO2013138776A1 (fr) | 2012-03-16 | 2013-09-19 | Merial Limited | Nouveaux procédés pour fournir une immunité de protection à long terme contre la rage chez des animaux, basés sur l'administration d'un flavivirus défectueux en termes de réplication, exprimant la rage g |
| WO2014100816A2 (fr) | 2012-12-21 | 2014-06-26 | University Of Miami | Agonistes de ghrh pour la greffe et fonction de cellules d'îlot et le traitement du diabète |
| EP2934565B1 (fr) | 2012-12-21 | 2019-03-13 | University of Miami | Agonistes de ghrh pour le traitement de troubles ischémiques |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4224316A (en) | 1979-03-30 | 1980-09-23 | Beckman Instruments, Inc. | Synthetic peptides having pituitary growth hormone releasing activity |
| US4223021A (en) | 1979-03-30 | 1980-09-16 | Beckman Instruments, Inc. | Synthetic peptides having pituitary growth hormone releasing activity |
| US4223020A (en) | 1979-03-30 | 1980-09-16 | Beckman Instruments, Inc. | Synthetic peptides having pituitary growth hormone releasing activity |
| US4226857A (en) | 1979-03-30 | 1980-10-07 | Beckman Instruments, Inc. | Synthetic peptides having pituitary growth hormone releasing activity |
| US4223019A (en) | 1979-03-30 | 1980-09-16 | Beckman Instruments, Inc. | Synthetic peptides having pituitary growth hormone releasing activity |
| US4228158A (en) | 1979-03-30 | 1980-10-14 | Beckman Instruments, Inc. | Synthetic peptides having pituitary growth hormone releasing activity |
| US4228156A (en) | 1979-03-30 | 1980-10-14 | Beckman Instruments, Inc. | Synthetic peptides having pituitary growth hormone releasing activity |
| US4410512A (en) | 1981-12-28 | 1983-10-18 | Beckman Instruments, Inc. | Combinations having synergistic pituitary growth hormone releasing activity |
| NL8200523A (nl) | 1982-02-11 | 1983-09-01 | Univ Leiden | Werkwijze voor het in vitro transformeren van planteprotoplasten met plasmide-dna. |
| US5134120A (en) | 1984-08-03 | 1992-07-28 | Cornell Research Foundation, Inc. | Use of growth hormone to enhance porcine weight gain |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5036045A (en) | 1985-09-12 | 1991-07-30 | The University Of Virginia Alumni Patents Foundation | Method for increasing growth hormone secretion |
| US4833166A (en) | 1987-05-01 | 1989-05-23 | Grosvenor Clark E | Growth hormone releasing hormone complementary peptides |
| US4839344A (en) | 1987-06-12 | 1989-06-13 | Eastman Kodak Company | Polypeptide compounds having growth hormone releasing activity |
| USRE33699E (en) | 1987-07-09 | 1991-09-24 | International Minerals & Chemical Corp. | Growth hormone-releasing factor analogs |
| FR2622455B1 (fr) | 1987-11-04 | 1991-07-12 | Agronomique Inst Nat Rech | Application du facteur de stimulation de la secretion de l'hormone de croissance humaine, de ses fragments actifs et des analogues correspondants, pour augmenter la production laitiere et le poids des nouveau-nes chez les mammiferes |
| US4952500A (en) | 1988-02-01 | 1990-08-28 | University Of Georgia Research Foundation, Inc. | Cloning systems for Rhodococcus and related bacteria |
| US4956288A (en) | 1988-04-22 | 1990-09-11 | Biogen, Inc. | Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA |
| US5023322A (en) | 1988-08-31 | 1991-06-11 | Mta Kutatas-Es Szervezetelemzo Intezete | Analogs of growth hormone releasing factor (GRF) and a method for the preparation thereof |
| US5084442A (en) | 1988-09-06 | 1992-01-28 | Hoffmann-La Roche Inc. | Cyclic growth hormone releasing factor analogs and method for the manufacture thereof |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5302523A (en) | 1989-06-21 | 1994-04-12 | Zeneca Limited | Transformation of plant cells |
| US5550318A (en) | 1990-04-17 | 1996-08-27 | Dekalb Genetics Corporation | Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof |
| US7705215B1 (en) | 1990-04-17 | 2010-04-27 | Dekalb Genetics Corporation | Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof |
| US5137872A (en) | 1989-09-18 | 1992-08-11 | Pitman-Moore, Inc. | Growth hormone-releasing factor analogs |
| US5322783A (en) | 1989-10-17 | 1994-06-21 | Pioneer Hi-Bred International, Inc. | Soybean transformation by microparticle bombardment |
| US5484956A (en) | 1990-01-22 | 1996-01-16 | Dekalb Genetics Corporation | Fertile transgenic Zea mays plant comprising heterologous DNA encoding Bacillus thuringiensis endotoxin |
| JPH06500311A (ja) | 1990-06-29 | 1994-01-13 | エフ・ホフマン―ラ ロシュ アーゲー | ヒスチジン置換されたヒト成長ホルモン放出因子類縁体 |
| US5486505A (en) | 1990-07-24 | 1996-01-23 | Polygen Holding Corporation | Polypeptide compounds having growth hormone releasing activity |
| US5384253A (en) | 1990-12-28 | 1995-01-24 | Dekalb Genetics Corporation | Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes |
| CA2084061A1 (fr) | 1991-04-09 | 1992-10-10 | Arthur M. Felix | Analogues du facteur liberant l'hormone de croissance |
| AU2515992A (en) | 1991-08-20 | 1993-03-16 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
| US5663146A (en) | 1991-08-22 | 1997-09-02 | Administrators Of The Tulane Educational Fund | Polypeptide analogues having growth hormone releasing activity |
| US5610042A (en) | 1991-10-07 | 1997-03-11 | Ciba-Geigy Corporation | Methods for stable transformation of wheat |
| US5298422A (en) | 1991-11-06 | 1994-03-29 | Baylor College Of Medicine | Myogenic vector systems |
| US5925564A (en) * | 1991-11-06 | 1999-07-20 | Baylor College Of Medicine | Expression vector systems and method of use |
| JP3368603B2 (ja) | 1992-02-28 | 2003-01-20 | オリンパス光学工業株式会社 | 遺伝子治療用処置具 |
| US6033884A (en) | 1992-03-20 | 2000-03-07 | Baylor College Of Medicine | Nucleic acid transporter systems and methods of use |
| ATE260679T1 (de) | 1992-04-03 | 2004-03-15 | Univ California | Selbstorganisierendes system zur verabreichung von polynukleotiden enthaltend ein amphiphatisches peptid |
| AU685054C (en) | 1992-05-14 | 2003-02-27 | Baylor College Of Medicine | Mutated steroid hormone receptors, methods for their use and molecular switch for gene therapy |
| EP0604662B1 (fr) | 1992-07-07 | 2008-06-18 | Japan Tobacco Inc. | Procede de transformation d'une monocotyledone |
| US5702932A (en) | 1992-07-20 | 1997-12-30 | University Of Florida | Microinjection methods to transform arthropods with exogenous DNA |
| WO1994002620A2 (fr) | 1992-07-27 | 1994-02-03 | Pioneer Hi-Bred International, Inc. | Procede ameliore de transformation induite par agrobacterium de cellules de soja cultivees |
| DE4228457A1 (de) | 1992-08-27 | 1994-04-28 | Beiersdorf Ag | Herstellung von heterodimerem PDGF-AB mit Hilfe eines bicistronischen Vektorsystems in Säugerzellen |
| GB9222888D0 (en) | 1992-10-30 | 1992-12-16 | British Tech Group | Tomography |
| US5439440A (en) | 1993-04-01 | 1995-08-08 | Genetronics, Inc. | Electroporation system with voltage control feedback for clinical applications |
| US5656610A (en) | 1994-06-21 | 1997-08-12 | University Of Southern California | Producing a protein in a mammal by injection of a DNA-sequence into the tongue |
| FR2722208B1 (fr) | 1994-07-05 | 1996-10-04 | Inst Nat Sante Rech Med | Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique |
| US5736524A (en) | 1994-11-14 | 1998-04-07 | Merck & Co.,. Inc. | Polynucleotide tuberculosis vaccine |
| US5792747A (en) | 1995-01-24 | 1998-08-11 | The Administrators Of The Tulane Educational Fund | Highly potent agonists of growth hormone releasing hormone |
| JPH11503454A (ja) | 1995-04-14 | 1999-03-26 | ジ アドミニストレイターズ オブ ザ チューレン エデュケイショナル ファンド | 成長ホルモン放出因子の類似体 |
| US5780448A (en) | 1995-11-07 | 1998-07-14 | Ottawa Civic Hospital Loeb Research | DNA-based vaccination of fish |
| US5928906A (en) | 1996-05-09 | 1999-07-27 | Sequenom, Inc. | Process for direct sequencing during template amplification |
| US5945100A (en) | 1996-07-31 | 1999-08-31 | Fbp Corporation | Tumor delivery vehicles |
| CA2264012C (fr) * | 1996-08-13 | 2011-04-26 | Chiron Corporation | Compositions et procedes d'apport de polynucleotides |
| US5981274A (en) | 1996-09-18 | 1999-11-09 | Tyrrell; D. Lorne J. | Recombinant hepatitis virus vectors |
| US5704908A (en) | 1996-10-10 | 1998-01-06 | Genetronics, Inc. | Electroporation and iontophoresis catheter with porous balloon |
| US6423693B1 (en) | 1997-07-24 | 2002-07-23 | Baylor College Of Medicine | Growth hormone releasing hormone expression system and methods of use, including use in animals |
| US5994624A (en) | 1997-10-20 | 1999-11-30 | Cotton Incorporated | In planta method for the production of transgenic plants |
| US6194402B1 (en) | 1998-09-02 | 2001-02-27 | Merck & Co., Inc. | Enhancement of return to independent living status with a growth hormone secretagogue |
| JP2000350590A (ja) * | 1999-04-12 | 2000-12-19 | Pfizer Prod Inc | 成長ホルモン及び成長ホルモン放出ホルモン組成物 |
| EP1204321B1 (fr) * | 1999-07-26 | 2005-11-09 | Baylor College Of Medicine | Analogue superactif de la somatostatine porcine |
| EP1465654B1 (fr) * | 2001-12-11 | 2015-02-25 | Inovio Pharmaceuticals, Inc. | Supplementation induite par les plasmides dans le traitement de maladies chroniques affectant des sujets |
| AU2005287383B2 (en) * | 2004-05-25 | 2011-09-22 | Chimeros, Inc. | Self-assembling nanoparticle drug delivery system |
| US9302725B2 (en) | 2013-03-14 | 2016-04-05 | Bell Sports, Inc. | Locking rack system for bicycles |
| WO2015178959A1 (fr) | 2014-05-19 | 2015-11-26 | Felix Sorkin | Embout permanent modifié |
-
2002
- 2002-12-10 EP EP02804771.0A patent/EP1465654B1/fr not_active Expired - Lifetime
- 2002-12-10 CN CNA02827105XA patent/CN1615151A/zh active Pending
- 2002-12-10 CA CA2469310A patent/CA2469310C/fr not_active Expired - Lifetime
- 2002-12-10 WO PCT/US2002/039509 patent/WO2003049700A2/fr not_active Application Discontinuation
- 2002-12-10 US US10/315,907 patent/US7241744B2/en not_active Expired - Lifetime
- 2002-12-10 TW TW091135752A patent/TW200301778A/zh unknown
- 2002-12-10 MX MXPA04005713A patent/MXPA04005713A/es not_active Application Discontinuation
- 2002-12-10 MY MYPI20024609A patent/MY142457A/en unknown
- 2002-12-10 AR ARP020104785A patent/AR037778A1/es not_active Application Discontinuation
- 2002-12-10 AU AU2002357143A patent/AU2002357143B2/en not_active Expired
- 2002-12-10 BR BR0214869-2A patent/BR0214869A/pt not_active Application Discontinuation
-
2007
- 2007-03-21 US US11/726,291 patent/US8178504B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20090170748A1 (en) | 2009-07-02 |
| MY142457A (en) | 2010-11-30 |
| EP1465654B1 (fr) | 2015-02-25 |
| CA2469310C (fr) | 2013-01-29 |
| US7241744B2 (en) | 2007-07-10 |
| TW200301778A (en) | 2003-07-16 |
| AU2002357143A1 (en) | 2003-06-23 |
| EP1465654A4 (fr) | 2007-08-29 |
| AR037778A1 (es) | 2004-12-01 |
| MXPA04005713A (es) | 2005-06-06 |
| EP1465654A2 (fr) | 2004-10-13 |
| BR0214869A (pt) | 2005-03-08 |
| WO2003049700A3 (fr) | 2003-09-18 |
| WO2003049700A2 (fr) | 2003-06-19 |
| CN1615151A (zh) | 2005-05-11 |
| CA2469310A1 (fr) | 2003-06-19 |
| AU2002357143B2 (en) | 2009-07-30 |
| US20040057941A1 (en) | 2004-03-25 |
| US8178504B2 (en) | 2012-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2003049700B1 (fr) | Supplementation induite par les plasmides dans le traitement de maladies chroniques affectant des sujets | |
| Cemazar et al. | Cancer electrogene therapy with interleukin-12 | |
| CA1306212C (fr) | Analogues d'insuline et procede de preparation | |
| EP0963207B1 (fr) | IL12 pour la thérapie génique des tumeurs | |
| EP1543020B1 (fr) | Plasmides synthetiques optimises par codons | |
| WO2003038112B1 (fr) | Composition et methode permettant de modifier la masse maigre et les proprietes osseuses d'un sujet | |
| IL173158A (en) | Polypeptide having an improved cytosine deaminase activity | |
| US6001816A (en) | Gene therapy for leptin deficiency | |
| KR102267837B1 (ko) | 재조합 백시니아 바이러스 및 이를 포함하는 약학 조성물 | |
| CN1720066A (zh) | 应用在肿瘤低氧区域中选择性复制的重组腺病毒载体的靶向肿瘤治疗 | |
| CA2252470A1 (fr) | Traitement du cancer chez l'homme par un vecteur adenoviral contenant un gene consensus d'interferon | |
| CN1744919A (zh) | 使用凋亡的选择性诱导来治疗肿瘤的方法和组合物 | |
| CN113499450B (zh) | 用于治疗疼痛的组合物 | |
| WO2007087462A9 (fr) | Méthodes et compositions destinées au traitement du cancer, dans lesquelles est utilisé un nouvel adénovirus | |
| WO1997048419A1 (fr) | Therapie genique de l'obesite | |
| EP1458240B1 (fr) | Constructions d'acide nucleique utiles pour la production regulee de glucose d'insuline humaine dans des souches de cellules somatiques | |
| DK1618197T3 (en) | DOG GHRH GENES, POLYPEPTIDES AND METHODS OF USE | |
| EP1218508B1 (fr) | Séquences d'ADN pour accroître l'efficacité de l'alimentation et la vitesse de croissance des porcins | |
| US20050164946A1 (en) | Canine GHRH gene, polypeptides and methods of use | |
| Paulssen et al. | Specific antisense RNA inhibition of growth hormone production in differentiated rat pituitary tumour cells | |
| EP1121449A1 (fr) | Systeme d'administration de somatotropine porcine | |
| EP1513559A1 (fr) | Delivrance augmentee d un produit de recombinaison d acide nucleique in vivo par le systeme poly-l-glutamate (plg) | |
| US20050032728A1 (en) | Tumor suppression through bicistronic co-expression of p53 and p14ARF | |
| KR100313559B1 (ko) | 수용성 TGFβ 수용체를 발현하는 재조합 세포주 및 전기세포주를 이용한 암치료 방법 | |
| US20010010926A1 (en) | New immunoregulatory protein lst-1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| B | Later publication of amended claims |
Free format text: 20030916 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2469310 Country of ref document: CA |
|
| WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2004/005713 Country of ref document: MX |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2002357143 Country of ref document: AU |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2002804771 Country of ref document: EP Ref document number: 534027 Country of ref document: NZ |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2002827105X Country of ref document: CN |
|
| WWP | Wipo information: published in national office |
Ref document number: 2002804771 Country of ref document: EP |
|
| NENP | Non-entry into the national phase |
Ref country code: JP |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: JP |